多能性ヒトMesoangioblastsの末梢血中への動員メカニズムの解明

阐明多能人中成血管细胞招募外周血的机制

• 批准号: 22890220
• 负责人: 岩崎 真佳
• 金额: $ 1.96万
• 依托单位: Kansai Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Research Activity Start-up
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-22890220/
• 关键词: 再生医療; トランスレーショナルリサーチ

心機能障害を持つ患者に対し、幹細胞・前駆細胞療法は有望な治療方法である。現在主に臨床応用されているのは自己骨髄細胞であるが、われわれがごく最近報告した多能性ヒトMesoangioblasts(MAB)は末梢血中に存在し、骨髄細胞よりも高い増殖能、分化能を有していると考えられる。今回の研究の目的はこの細胞が末梢循環血中に動員されるメカニズムを解析し、末梢循環血中に動員されるきっかけとなりうる因子を同定し、この大きな可能性を秘めた細胞の臨床応用を少しでも容易なものにすることである。これまでの我々の検討ではhepatocyte growth factor (HGF)がMABの末梢血中への動員に強く関与していることが示唆されている。それでは、開心術中に患者血漿中でのHGFの増加に寄与した因子はなんであろうか?これまでの数多くの報告から人工心肺とヘパリン、そして一般的な外科的侵襲が考えられる。ヘパリンは静脈内投与後、約5分で血漿中HGF濃度を上昇させることが報告されている。そこでわれわれは本学の臨床研究倫理委員会の承認を得て、昨年秋からまず、人工心肺がcMABの動員に必須であるかどうかということから検討を始めた。方法として開心術を行う患者の(1)人工心肺装着前と(2)人工心肺離脱時のプロタミン投与直前の2つのタイミングで中心静脈から採血を行いcMABの獲得が可能かどうか検討した。結果、(1)、(2)の両方のタイミングでcMABを獲得できることが判明し(獲得率100%;症例数:7人)、cMABの末梢血中への動員に関与する因子として「ヘパリン→血漿中HGF濃度↑」が考えられた。この結果を受け、今後われわれはcMABの臨床応用をより可能性の高いものとするべく、「ヘパリンとcMABの末梢血中への動員との関連(交付申請書の研究計画の2番)」により重点をおいて次年度は研究を行う。

Cardiac dysfunction can damage the patients with chronic hepatitis, and the method of precellular cytology is expected to treat the patients with heart failure. Now, in the main body of the bed, it has been recently reported that there is a presence in the peripheral blood of pluripotent cells Mesoangioblasts (MAB), bone cells have high reproductive capacity and differentiation ability. The purpose of this study is to analyze the end of the cell in the blood, and to determine the factors of the cell in the blood, the possibility and the possibility to use a small number of cells in the blood, and it is easy to use a small number of cells. Please tell me that the hepatocyte growth factor (HGF) MAB has been forced to be activated by the operator in the peripheral blood, and that you have been told to instigate it. In the blood of patients undergoing cardiac surgery and cardiac surgery, there is a significant increase in the number of HGF in the blood of patients with cardiac surgery and cardiac surgery. There are a lot of reports on artificial heart and lung disease and general surgical intrusions. After the intravenous injection, about 5% of the HGF in the blood was reported. The committee of the management committee of the University of Science and Technology acknowledges that it is necessary for the cMAB operator of the artificial heart and lungs to make sure that it is necessary to make sure that it is necessary to improve the performance of the staff. Methods the patients undergoing open heart surgery were divided into two groups: (1) the artificial heart and lung were installed in the front. (2) during the isolation of the artificial heart and lung, the heart and lung were placed in front of the patient. The heart and lung were separated from the heart and lung. The heart and lung were placed in the center of the heart and lung. The heart and lung were separated from the heart and lung. The heart and lung were placed in front of the heart and lung. The heart and lung were separated from the heart and lung. The heart and lung were separated from the heart and lung. The heart and lung were placed in front of the heart and lungs. The heart and lung were separated from the heart and lungs. Results: (1), (2) the results showed that cMAB was confirmed by Elisa (the rate of success was 100%; the number of cases: 7), and the levels of HGF in peripheral blood of patients with cMAB were detected by Elisa. The results show that in the future, there is a high probability that the cMAB will be used in the future, and that the health care providers in the peripheral blood of the cMAB will be responsible for the second time of the application study plan.